2 Nasdaq-100 Stocks to Buy Before They Soar 105% and 130%, According to Wall Street

Wall Street median targets imply 126% upside for CoreWeave ($142.50 versus $62) and 105% for Rocket Lab ($105 versus $51), though these are analyst estimates, not guaranteed returns. CoreWeave’s Q2 revenue rose 112% to $2.5 billion, but its non-GAAP net loss widened to $567 million amid infrastructure financing costs. Rocket Lab’s Q2 revenue rose 62% to $234 million and backlog reached a record $2.3 billion, up 137%; it remains unprofitable and trades at 39 times sales, with SpaceX competition adding risk.

Analysis

The analyst targets are not catalysts: they extrapolate growth and should carry little weight without evidence of cash conversion. CRWV: Near term, AI-capacity scarcity can support utilization and pricing, but the second-order risk is that capex and interest costs grow faster than monetizable workloads. More GPU supply, hyperscaler self-builds/custom silicon, or weaker customer returns on AI spending could pressure rental rates before reported demand rolls over. NVIDIA benefits from infrastructure orders, but CRWV’s financing and utilization economics are not equivalent to NVIDIA’s; watch whether customer demand converts into durable GPU deployments rather than merely shifting capex forward. Over 1–3 months, focus on capex, financing terms, utilization/pricing, and cash flow—not revenue growth alone. RKLB: Backlog only creates value if it converts to launches and space-systems revenue at acceptable margins. Neutron schedule slips, launch cadence constraints, or aggressive pricing from SpaceX could delay conversion and compress an already demanding sales multiple. The key 6–18 month test is execution and cash required to scale, not the size of the addressable space market. A broad risk-off move in long-duration growth would likely hit RKLB harder. Falsifiers: CRWV shows improving cash generation without worsening financing burden; or RKLB delivers milestones and backlog conversion while controlling cash burn. Conversely, weaker AI-capex guidance or a material Neutron delay would undermine the respective bull cases.

Key Decisions for Investors

• Do not trade the stated target-price upside as a signal. For CRWV, consider only a small, staged long after verifying current financing costs, capex commitments, utilization/pricing, and cash-flow trajectory; pause if debt/interest growth outpaces evidence of workload monetization.
• Prefer NVIDIA over CRWV for a cleaner AI-infrastructure expression if the thesis is rising GPU demand, while recognizing that NVIDIA is still exposed to a reversal in customer capex. Reassess on hyperscaler capex guidance and evidence of GPU supply easing.
• Keep RKLB on a catalyst watchlist rather than chasing a backlog narrative at a premium valuation. Revisit after observable Neutron milestones and backlog conversion; reduce or avoid exposure if schedule slippage or cash burn worsens.
• No high-conviction pair trade is warranted from this article alone. Track CRWV financing/cash-flow metrics and RKLB milestone execution; those data, plus current valuation and options liquidity, are needed before sizing a relative-value or options position.